1
|
Baskar S, Veldtman GR, Khoury PR, Opotowsky AR, Cedars AM. Characteristics of hospital admissions associated with implantable cardioverter defibrillator placement among adults with congenital heart disease. Int J Cardiol 2018; 269:97-103. [PMID: 30060972 DOI: 10.1016/j.ijcard.2018.07.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Revised: 06/08/2018] [Accepted: 07/18/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND Characteristics of hospitalizations including healthcare utilization for adult patients with congenital heart disease (ACHD) at the time of implantable cardioverter defibrillator (ICD) placement has not been well studied. METHODS We analyzed data from the 2002-2014 United States National Inpatient Sample (NIS). ICD implantation, CHD, complications, and indications for admissions were determined based on diagnostic codes among adults. Propensity score matching was performed, based on age, sex and in-hospital mortality index with a 10:1 ratio between adults without CHD and those with CHD, to determine relative healthcare utilization attributable to CHD. RESULTS ACHD accounted for 136,509 ± 3488 admissions of which 1451 ± 121 admissions (1.1 ± 0.06%) were associated with an ICD placement. ICD placement occurred most frequently among patients with TOF, VSD, and transposition complexes usually in the context of a dysrhythmia. Compared to those without CHD, ACHD patients had higher adjusted total hospital charges ($147,002 ± 5516 vs $132,455 ± 2182; p < 0.001), length of stay (6.2 ± 0.5 vs 5.2 ± 0.1 days; p < 0.001), lower readmission score (5.5 ± 0.5 vs 9.7 ± 0.1; p = 0.04) and a higher complication rate (13.4% vs 8.3%; p < 0.001). Dysrhythmias were more frequently the primary diagnosis for admission in the ACHD cohort (63% vs 38%; p < 0.001). CONCLUSION Compared to a matched non-CHD population, ACHD patients had greater healthcare utilization and had more frequent complications. The reasons underlying this difference bear investigation to improve care quality.
Collapse
Affiliation(s)
- Shankar Baskar
- The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
| | - Gruschen R Veldtman
- The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Philip R Khoury
- The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Alexander R Opotowsky
- Department of Cardiology, Boston Children's Hospital, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - Ari M Cedars
- Division of Cardiology, University of Texas Southwestern Medical School, Dallas, TX, USA
| |
Collapse
|
2
|
Stewart MH, Macicek SL, Morin DP. Implantable Cardioverter-defibrillators in Adult Congenital Heart Disease. J Innov Card Rhythm Manag 2018; 9:3172-3181. [PMID: 32494493 PMCID: PMC7252815 DOI: 10.19102/icrm.2018.090601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Accepted: 11/29/2017] [Indexed: 11/30/2022] Open
Abstract
With improved surgical techniques and medical therapies, many patients who are born with complex congenital heart defects are now living well into adulthood. As these patients age, an increasingly common cause of mortality is sudden cardiac death (SCD) from ventricular tachyarrhythmias. The implantable cardioverter-defibrillator (ICD) is a therapy with the ability to prevent some of these deaths; however, there are many diagnostic and technical challenges that remain in the congenital heart disease (CHD) population. We performed a literature review, searching PubMed for articles that examined the role of ICDs in CHD. We herein present the evidence for when to place an ICD in CHD patients, stratified by subtype as relevant. Then, we discuss the technical challenges and complications that are unique to this patient population. We conclude that, despite active work in the area, more research is needed given the small event rates and clinical variability within CHD populations.
Collapse
Affiliation(s)
- Merrill H Stewart
- Department of Cardiology, Ochsner Medical Center, New Orleans, LA, USA
| | - Scott L Macicek
- Department of Pediatric Cardiology, Ochsner Medical Center, New Orleans, LA, USA
| | - Daniel P Morin
- Department of Cardiology, Ochsner Medical Center, New Orleans, LA, USA.,Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA, USA
| |
Collapse
|
3
|
Baysa SJ, Olen M, Kanter RJ. Arrhythmias Following the Mustard and Senning Operations for Dextro-Transposition of the Great Arteries: Clinical Aspects and Catheter Ablation. Card Electrophysiol Clin 2017; 9:255-271. [PMID: 28457240 DOI: 10.1016/j.ccep.2017.02.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The atrial switch operations, the Mustard and Senning procedures, performed for dextro-transposition of the great arteries, have largely been supplanted by the arterial switch operation. As such, affected patients will only exist for approximately 30 more years. The main arrhythmias in these patients include sinoatrial node dysfunction, intraatrial reentry tachycardia, and sudden death. Device therapy for these patients is well-established, and catheter ablation for atrial tachycardias is highly efficacious. The application of meticulous procedural planning, customization of catheter courses, and electrophysiologic principles to this patient group may be extended to all postoperative complex congenital heart patients.
Collapse
Affiliation(s)
- Sherrie Joy Baysa
- Division of Cardiology, Nicklaus Children's Hospital, Miami, FL 33155, USA
| | - Melissa Olen
- Division of Cardiology, Nicklaus Children's Hospital, Miami, FL 33155, USA
| | - Ronald J Kanter
- Division of Cardiology, Nicklaus Children's Hospital, Miami, FL 33155, USA.
| |
Collapse
|
4
|
|
5
|
BACKHOFF DAVID, KERST GUNTER, PETERS ANDREA, LÜDEMANN MONIKA, FRISCHE CHRISTIAN, HORNDASCH MICHAELA, HESSLING GABRIELE, PAUL THOMAS, KRAUSE ULRICH. Internal Cardioverter Defibrillator Indications and Therapies after Atrial Baffle Procedure for d-Transposition of the Great Arteries: A Multicenter Analysis. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2016; 39:1070-1076. [DOI: 10.1111/pace.12933] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 06/28/2016] [Accepted: 07/17/2016] [Indexed: 12/31/2022]
Affiliation(s)
- DAVID BACKHOFF
- Department of Pediatric Cardiology; Georg-August-University; Göttingen Germany
| | - GUNTER KERST
- Pediatric Heart Center; Justus-Liebig-University; Gießen Germany
| | - ANDREA PETERS
- Pediatric Heart Center; Justus-Liebig-University; Gießen Germany
| | - MONIKA LÜDEMANN
- Pediatric Heart Center; Justus-Liebig-University; Gießen Germany
| | - CHRISTIAN FRISCHE
- Department of Pediatric Cardiology; University Children's Hospital; Tübingen Germany
| | | | | | - THOMAS PAUL
- Department of Pediatric Cardiology; Georg-August-University; Göttingen Germany
| | - ULRICH KRAUSE
- Department of Pediatric Cardiology; Georg-August-University; Göttingen Germany
| |
Collapse
|
6
|
Moore JP, Mondésert B, Lloyd MS, Cook SC, Zaidi AN, Pass RH, John AS, Fish FA, Shannon KM, Aboulhosn JA, Khairy P. Clinical Experience With the Subcutaneous Implantable Cardioverter–Defibrillator in Adults With Congenital Heart Disease. Circ Arrhythm Electrophysiol 2016; 9:CIRCEP.116.004338. [DOI: 10.1161/circep.116.004338] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2016] [Accepted: 08/15/2016] [Indexed: 11/16/2022]
Abstract
Background—
Sudden cardiac death is a major contributor to mortality for adults with congenital heart disease. The subcutaneous implantable cardioverter–defibrillator (ICD) has emerged as a novel tool for prevention of sudden cardiac death, but clinical performance data for adults with congenital heart disease are limited.
Methods and Results—
A retrospective study involving 7 centers over a 5-year period beginning in 2011 was performed. Twenty-one patients (median 33.9 years) were identified. The most common diagnosis was single ventricle physiology (52%), 9 palliated by Fontan operation and 2 by aortopulmonary shunts:
d
-transposition of the great arteries after Mustard/Senning (n=2), tetralogy of Fallot (n=2), aortic valve disease (n=2), and other biventricular surgery (n=4). A prior cardiac device had been implanted in 7 (33%). The ICD indication was primary prevention in 67% and secondary in 33% patients. The most common reason for subcutaneous ICD placement was limited transvenous access for ventricular lead placement (n=10) followed by intracardiac right-to-left shunt (n=5). Ventricular arrhythmia was induced in 17 (81%) and was converted with ≤80 Joules in all. There was one implant complication related to infection, not requiring device removal. Over a median follow-up of 14 months, 4 patients (21%) received inappropriate and 1 (5%) patient received appropriate shocks. There was one arrhythmic death related to asystole in a single ventricle patient.
Conclusions—
Subcutaneous ICD implantation is feasible for adults with congenital heart disease patients. Most candidates have single ventricle heart disease and limited transvenous options for ICD placement. Despite variable anatomy, this study demonstrates successful conversion of induced ventricular arrhythmia and reasonable rhythm discrimination during follow-up.
Collapse
Affiliation(s)
- Jeremy P. Moore
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Blandine Mondésert
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Michael S. Lloyd
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Stephen C. Cook
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Ali N. Zaidi
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Robert H. Pass
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Anitha S. John
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Frank A. Fish
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Kevin M. Shannon
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Jamil A. Aboulhosn
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| | - Paul Khairy
- From the Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA (J.P.M., K.M.S., J.A.A.); Montreal Heart Institute, Montreal, QC, Canada (B.M., P.K.); Emory University School of Medicine, Atlanta, GA (M.S.L.); Children’s Heart Institute of Pittsburgh, Pittsburgh, PA (S.C.C.); Montefiore Medical Center, Bronx, NY (A.N.Z., R.H.P.); Children’s National Medical Center, Washington, DC (A.S.J.); and Vanderbilt University, Nashville, TN (F.A.F.)
| |
Collapse
|
7
|
Vehmeijer JT, Brouwer TF, Limpens J, Knops RE, Bouma BJ, Mulder BJM, de Groot JR. Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis. Eur Heart J 2016; 37:1439-48. [PMID: 26873095 DOI: 10.1093/eurheartj/ehv735] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 12/13/2015] [Indexed: 11/13/2022] Open
Abstract
AIMS Sudden cardiac death is a major cause of mortality in adult congenital heart disease (ACHD) patients. The indications for implantable cardioverter-defibrillator (ICD) implantation in ACHD patients are still not well established. We aim to systematically review the literature on indications and outcome of ICD implantation in ACHD patients. METHODS AND RESULTS We performed a comprehensive search in EMBASE, MEDLINE, and Google Scholar to identify all studies on ICD implantation in ACHD patients. We used random effects models to calculate proportions and 95% confidence intervals. Of 1356 articles, 24 studies with 2162 patients were included, with a mean follow-up of 3.6 ± 0.9 years. Half of patients had tetralogy of Fallot. Mean age at implantation was 36.5 ± 5.5 years old and 66% was male. Implantable cardioverter-defibrillators were implanted for primary prevention in 53% (43.5-62.7). Overall, 24% (18.6-31.3) of patients received one or more appropriate ICD interventions (anti-tachycardia pacing or shocks) during 3.7 ± 0.9 years: 22% (16.9-28.8) of patients with primary prevention in 3.3 ± 0.3 years and 35% (26.6-45.2) of patients with secondary prevention in 4.3 ± 1.2 years. Inappropriate shocks occurred in 25% (20.1-31.0) in 3.7 ± 0.8 years and other, particularly lead-related complications in 26% (18.9-33.6) of patients in 3.8 ± 0.8 years. All-cause mortality was 10% during 3.7 ± 0.9 years. CONCLUSIONS In ACHD, remarkably high rates of appropriate ICD therapy were reported, both in primary and secondary prevention. Because of the young age and lower death rates, the cumulative beneficial effects are likely greater in ACHD patients than in acquired heart disease patients. However, considering the high rates of inappropriate shocks and complications, case-by-case weighing of costs and benefits, remains essential.
Collapse
Affiliation(s)
- Jim T Vehmeijer
- Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands
| | - Tom F Brouwer
- Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands
| | | | - Reinoud E Knops
- Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands
| | - Berto J Bouma
- Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands
| | - Barbara J M Mulder
- Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands
| | - Joris R de Groot
- Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands
| |
Collapse
|
8
|
Sodhi SS, Cedars AM. Primary Prevention of Sudden Cardiac Death in Adults with Transposition of the Great Arteries: A Review of Implantable Cardioverter-Defibrillator Placement. Tex Heart Inst J 2015; 42:309-18. [PMID: 26413012 DOI: 10.14503/thij-14-4352] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Transposition of the great arteries encompasses a set of structural congenital cardiac lesions that has in common ventriculoarterial discordance. Primarily because of advances in medical and surgical care, an increasing number of children born with this anomaly are surviving into adulthood. Depending upon the subtype of lesion or the particular corrective surgery that the patient might have undergone, this group of adult congenital heart disease patients constitutes a relatively new population with unique medical sequelae. Among the more common and difficult to manage are cardiac arrhythmias and other sequelae that can lead to sudden cardiac death. To date, the question of whether implantable cardioverter-defibrillators should be placed in this cohort as a preventive measure to abort sudden death has largely gone unanswered. Therefore, we review the available literature surrounding this issue.
Collapse
|
9
|
Implantable cardiac defibrillator among adults with transposition of the great arteries and atrial switch operation: case series and review of literature. Int J Cardiol 2014; 177:301-6. [PMID: 25499397 DOI: 10.1016/j.ijcard.2014.09.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Revised: 09/08/2014] [Accepted: 09/15/2014] [Indexed: 11/22/2022]
Abstract
BACKGROUND The experience with the implantable cardiac defibrillator (ICD) in patients with transposition of the great arteries (TGA) and history of atrial switch surgery remains limited. METHODS Retrospective evaluation aiming to assess characteristics and outcomes of consecutive TGA patients with history of atrial switch surgery implanted with an ICD between January 2005 and June 2012 in four French centers. RESULTS Of the 12 patients (median 34 years [28, 40]; 67% male), 4 patients (33%) were implanted for secondary prevention after symptomatic documented sustained ventricular tachycardia or sudden cardiac arrest. ICDs were implanted for primary prevention in 8 patients (67%), including cardiac resynchronization in 3 patients; severe systemic ventricle dysfunction was present in all cases (median ejection fraction 27% [20, 40]). Overall, one patient died during the ICD implantation secondary to refractory cardiac arrest after defibrillation testing. Over a median follow-up of 19 months [10, 106], 6 patients out of 11 (54%) experienced worsening of congestive heart failure, including 5 who were eventually transplanted. Overall, 3 patients (27%) experienced significant ICD-related complications, whereas only one patient (primary prevention indication) developed appropriate ICD therapy (successful anti-tachycardia pacing without shock). Half of the patients presented with at least one episode of sustained (≥ 5 min) atrial arrhythmia during follow-up. CONCLUSIONS Our findings underline the key role of progressive heart failure in dictating outcomes among TGA patients with prior atrial switch repair. Our results also underline the need of better risk-stratification for sudden cardiac death in those patients.
Collapse
|
10
|
ICD therapy for primary prevention of sudden cardiac death after Mustard repair for d-transposition of the great arteries. Clin Res Cardiol 2014; 103:894-901. [DOI: 10.1007/s00392-014-0727-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Accepted: 05/08/2014] [Indexed: 01/24/2023]
|
11
|
Mele M, Di Crecchio A, Villella A. Implant of a defibrillator in a 'Mustard patient' for primary prevention of sudden cardiac death: special considerations. J Cardiovasc Med (Hagerstown) 2013; 14:171-3. [PMID: 23303311 DOI: 10.2459/jcm.0b013e3283528f77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Joerg L, Bridgman C, Selvanayagam JB. Imaging cardio-vascular anatomy and function in D-Transposition of the great arteries after mustard procedure. Heart Lung Circ 2011; 20:666-8. [PMID: 21925396 DOI: 10.1016/j.hlc.2011.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Revised: 02/24/2011] [Accepted: 03/07/2011] [Indexed: 10/17/2022]
Abstract
We used cardiovascular magnetic resonance (CMR) to demonstrate cardio-vascular anatomy and function in a 42 year-old man with a D-Transposition of the great arteries who survived a sudden cardiac arrest.
Collapse
Affiliation(s)
- Lucas Joerg
- Department of Cardiovascular Medicine, Flinders Medical Centre, Flinders University, Flinders Drive, Bedford Park, 5042 South Australia, Australia
| | | | | |
Collapse
|
13
|
Frutos M, Arana E, Pedrote A, Rodríguez-Puras MJ. Cardioverter-defibrillator implantation in a patient with D-transposition of the great arteries with Mustard's physiologic correction. Rev Esp Cardiol 2009; 62:1193-4. [PMID: 19793527 DOI: 10.1016/s1885-5857(09)73336-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Frutos M, Arana E, Pedrote A, Rodríguez-Puras MJ. Implante de desfibrilador en un paciente con D-transposición de grandes arterias y corrección fisiológica de Mustard. Rev Esp Cardiol 2009. [DOI: 10.1016/s0300-8932(09)72390-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Schwerzmann M, Salehian O, Harris L, Siu SC, Williams WG, Webb GD, Colman JM, Redington A, Silversides CK. Ventricular arrhythmias and sudden death in adults after a Mustard operation for transposition of the great arteries. Eur Heart J 2009; 30:1873-9. [DOI: 10.1093/eurheartj/ehp179] [Citation(s) in RCA: 127] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Khairy P, Harris L, Landzberg MJ, Fernandes SM, Barlow A, Mercier LA, Viswanathan S, Chetaille P, Gordon E, Dore A, Cecchin F. Sudden Death and Defibrillators in Transposition of the Great Arteries With Intra-atrial Baffles. Circ Arrhythm Electrophysiol 2008; 1:250-7. [DOI: 10.1161/circep.108.776120] [Citation(s) in RCA: 201] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- Paul Khairy
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Louise Harris
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Michael J. Landzberg
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Susan M. Fernandes
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Amanda Barlow
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Lise-Andrée Mercier
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Sangeetha Viswanathan
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Philippe Chetaille
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Elaine Gordon
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Annie Dore
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| | - Frank Cecchin
- From the Canadian Adult Congenital Heart Network, Montreal, Quebec, Canada (P.K., L.H., A.B., L.A.M., P.C., E.G., A.D.); Leeds General Infirmary, Leeds, United Kingdom (S.V., P.C.); and Children’s Hospital, Boston, Mass (P.K., M.J.L., S.M.F., F.C.)
| |
Collapse
|